VP of R&D Resigns, Demands $1.29M Severance Citing Change in Control
BRTX is trading near its 52-week low of $2.61 (6.9% above the low).
Summary
BioRestorative Therapies' VP of R&D resigned, claiming a Change in Control and demanding $1.29M in severance. The Board disputes the claim and has launched an investigation into the employment agreements.
Key Events · Executive and Board Changes · BRTX
-
VP of R&D Resigns
Mr. Silva resigned as VP of Research and Development effective September 4, 2026, asserting 'Good Reason' based on a Change in Control.
-
$1.29M Severance Demand
Mr. Silva asserts entitlement to approximately $1.29 million in cash severance, acceleration of outstanding equity awards, and continuation of benefits.
-
Board Disputes Claim
The Board has not accepted the validity of the Employment Agreement or the Change in Control characterization, and has reserved all rights, claims, and defenses.
-
Investigation Authorized
The Board has authorized an investigation by special counsel into the negotiation, approval, execution, and amendment of the Employment Agreement and the agreements with the former CEO and CFO.
Analysis · BRTX · Industrial Applications And Services
BioRestorative Therapies' VP of Research and Development, Mr. Silva, resigned effective September 4, 2026, asserting 'Good Reason' based on a Change in Control and demanding approximately $1.29 million in cash severance plus equity acceleration. This is the third executive departure in two months following the CEO and CFO resignations in July, deepening the leadership vacuum at a company already facing a Nasdaq delisting notice, suspended product shipments, and a going concern warning. The Board disputes the validity of the Employment Agreement and has authorized an investigation into how these agreements were negotiated, signaling potential governance failures. The resignation removes the company's R&D leadership at a critical time when its core biocosmeceutical products are suspended pending regulatory review.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRTX was trading at $2.79 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $2.61 to $34.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.